Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease
Orginal Article |
Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus
Wei-Xing Ma1,2,3, Jing Tang3, Zhi-Wen Lei3, Chun-Yan Li1,4, Li-Qing Zhao3, Chao Lin3, Tao Sun3, Zheng-Yi Li3, Ying-Hui Jiang3, Jun-Tao Jia3, Cheng-Zhu Liang3, Jun-Hong Liu2, Liang-Jun Yan1,*
1Department of Pharmaceutical, University of North Texas Health Science Center, Fort Worth, Texas, USA
2Chemical Engineering Institute, Qingdao University of Science and Technology, Qingdao, Shandong, China
3Technological Center, Qingdao Customs, Qingdao, Shandong, China
4Shantou University Medical College, Shantou, Guangdong, China
Download: PDF(595 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

The goal of this review was to summarize current biochemical mechanisms of and risk factors for diabetic brain injury. We mainly summarized mechanisms published in the past three years and focused on diabetes induced cognitive impairment, diabetes-linked Alzheimer’s disease, and diabetic stroke. We think there is a need to conduct further studies with increased sample sizes and prolonged period of follow-ups to clarify the effect of DM on brain dysfunction. Additionally, we also think that enhancing experimental reproducibility using animal models in conjunction with application of advanced devices should be considered when new experiments are designed. It is expected that further investigation of the underlying mechanisms of diabetic cognitive impairment will provide novel insights into therapeutic approaches for ameliorating diabetes-associated injury in the brain.

Keywords diabetes      brain      cognitive impairment      Alzheimer’s disease      stroke     
Corresponding Authors: Liang-Jun Yan   
Just Accepted Date: 23 September 2019  
E-mail this article
E-mail Alert
Articles by authors
Wei-Xing Ma
Jing Tang
Zhi-Wen Lei
Chun-Yan Li
Li-Qing Zhao
Chao Lin
Tao Sun
Zheng-Yi Li
Ying-Hui Jiang
Jun-Tao Jia
Cheng-Zhu Liang
Jun-Hong Liu
Liang-Jun Yan
Cite this article:   
Wei-Xing Ma,Jing Tang,Zhi-Wen Lei, et al. Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus[J]. Aging and disease, 10.14336/AD.2019.0910
URL:     OR
Figure 1.  Signaling pathways and risk factors that are potentially involved in development of cognitive impairment induced by diabetes.
Figure 2.  Signaling pathways and risk factors that are potentially involved in diabetic AD.
Figure 3.  Signaling pathways and risk factors potentially involved in diabetic stroke.
[1] Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MrLF, et al. (2009). (Pre) diabetes, brain aging, and cognition. Biochim Biophys Acta, 1792:432-443.
[2] Toth C (2014). Chapter 32-Diabetes and neurodegeneration in the brain. Handbook of Clinical Neurology, 126:489-511.
[3] Guo S, Deng W, Xing C, Zhou Y, Ning M, Lo EH (2019). Effects of aging, hypertension and diabetes on the mouse brain and heart vasculomes. Neurobiol Dis, 126:117-123.
[4] Eisenhut M (2018). In diabetic ketoacidosis brain injury including cerebral oedema and infarction is caused by interleukin-1. Med Hypotheses, 121:44-46.
[5] Vargas R, Rincón J, Pedreañez A, Viera N, Hernández-Fonseca JP, Peña C, et al. (2012). Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats. Brain Res, 1453:64-76.
[6] Wisse LEM, Bresser Jd, Geerlings MI, Reijmer YD, Portegies MLP, Brundel M, et al. (2014). Global brain atrophy but not hippocampal atrophy is related to type 2 diabetes. J Neurol Sci, 344:32-36.
[7] Wrighten SA, Piroli GG, Grillo CA, Reagan LP (2009). A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta, 2009:444-453.
[8] Biessels GJ, Heide LPvd, Kamal A, Bleys RLAW, Gispen WH (2002). Ageing and diabetes: implications for brain function. Eur J Pharmacol, 441:1-14.
[9] Chen Z, Li L, Sun J, Ma L (2012). Mapping the brain in type II diabetes: Voxel-based morphometry using DARTEL. Eur J Radiol, 81:1870-1876.
[10] Thibault O, Anderson KL, DeMoll C, Brewer LD, Landfield PW, Porter NM (2013). Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. Eur J Pharmacol, 719:34-43.
[11] Schoenemann PT (2006). Evolution of the Size and Functional Areas of the Human Brain. Annu Rev Anthropol, 35:379-406.
[12] Rosenberg J, Lechea N, Pentang GN, Shah NJ (2019). What magnetic resonance imaging reveals - A systematic review of the relationship between type II diabetes and associated brain distortions of structure and cognitive functioning. Front Neuroendocrinol, 52:79-112.
[13] Cameron FJ (2015). The Impact of Diabetes on Brain Function in Childhood and Adolescence. Pediatr Clin N Am, 62:911-927.
[14] Hughes TM, Sink KM, Williamson JD, Hugenschmidt CE, Wagner BC, Whitlow CT, et al. (2018). Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes. Journal of Diabetes and Its Complications, 32:916-921.
[15] Bancks MP, Alonso A, Gottesman RF, Mosley TH (2017). Brain function and structure and risk for incident diabetes:The Atherosclerosis Risk in Communities Study. Alzheimer's & Dementia: the Journal of the Alzheimer's Association, 13:1345-1354.
[16] Groeneveld O, Reijmer Y, Heinen R, Kuijf H, Koekkoek P, Janssen J, et al. (2018). Brain imaging correlates of mild cognitive impairment and early dementia in patients with type 2 diabetes mellitus. Nutrition, Metabolism & Cardiovascular Diseases, 28:1253-1260.
[17] Hansen TM, Brock B, Juhl A, Drewes AM, Vorum H, Andersen CU, et al. (2019). Brain spectroscopy reveals that N-acetylaspartate is associated to peripheral sensorimotor neuropathy in type 1 diabetes. Journal of Diabetes and Its Complications, 33:323-328.
[18] Ergula A, Valenzuela JP, Fouda AY, Fagan SC (2015). Cellular connections, microenvironment and brain angiogenesis in diabetes: Lost communication signals in the post-stroke period. Brain Res, 1623:81-96.
[19] Arnal E, Miranda M, Johnsen-Soriano S, J.Romero F (2014). The Anti-Oxidative Component of Docosahexaenoic Acid (DHA) in the Brain in Diabetes. Diabetes: Oxidative Stress and Dietary Antioxidants, Chapter 13:129-134.
[20] Kooistra M, Geerlings MI, Mali WPTM, Vincken KL, Graaf Yvd, Biessels GJ (2013). Diabetes mellitus and progression of vascular brain lesions and brain atrophy in patients with symptomatic atherosclerotic disease. The SMART-MR study. J Neurol Sci, 332:69-74.
[21] MD FJC, Northam EA, Ryan CM (2019). The effect of type 1 diabetes on the developing brain. The Lancet Child & Adolescent Health, 3:427-436.
[22] Shahid MH, Verma A, Youngblood L (2018). From Mechanical to Chemical: A Case of Diabetes Insipidus Induced by Concussive Brain Injury. Am J Med, 131:e293-e294.
[23] Wu Y, Ye L, Yuan Y, Jiang T, Guo X, Wang Z, et al. (2019). Autophagy Activation is Associated with Neuroprotection in Diabetes-associated Cognitive Decline. Aging Dis, 10:1-13
[24] Park SY, Kim HY, Lee YS, Heo HJ, Shin HK, Lee WS, et al. (2019). Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model. Behav Brain Res, 365:133-140.
[25] M.A. A, Kumar MKM, Sabitha M, Menon KK, Nair SC (2019). Nanotechnology approaches for enhanced CNS delivery in treating T Alzheimer's disease. J Drug Deliv Sci Tec, 51:297-309.
[26] Macpherson H, Formica M, Harris E, Daly RM (2017). Brain functional alterations in Type 2 Diabetes - A systematic review of fMRI studies. Front Neuroendocrinol, 47:34-46.
[27] Song H-D, Kim SN, Saha A, Ahn S-Y, Akindehin S, Son Y, et al. (2020). Aging-Induced Brain-Derived Neurotrophic Factor in Adipocyte Progenitors Contributes to Adipose Tissue Dysfunction. Aging Dis, 11:1-13.
[28] Yang L, Yuan J, Zhou Z (2014). Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus. Can J Diabetes, 38:473-479.
[29] Qiao J, Li L, Ma Y, Shi R, Teng M (2018). Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice. Curr Res Translational Med, 67:89-92.
[30] Abdelwaheda OM, Tork OM, Din MMGe, L. Rashedb MZ (2018). Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive T functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin. Brain Res Bull, 139:67-80.
[31] Zheng T, Liu H, Qin L, Chen B, Zhang X, Hu X, et al. (2018). Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metab, 87:105-112.
[32] Chandran R, Kumar M, Kesavan L, Jacob RS, Gunasekaran S, Lakshmi S, et al. (2019). Cellular calcium signaling in the aging brain. J Chem Neuroanat, 95:95-114.
[33] Navakkode S, Liu C, Soong TW (2018). Altered function of neuronal L-type calcium channels in ageing and neuroinflammation:Implications in age-related synaptic dysfunction and cognitive decline. Aging Res Rev, 42:86-99.
[34] Grützner TM, Listunova L, Fabian GA, Kramer BA, Flach D, Weisbrod M, et al. (2018). Serum calcium levels and neuropsychological performance in depression and matched healthy controls: Reversal of correlation a marker of the aging cognitive clock? Psychoneuroendocrino, 91:198-205.
[35] Sharma A, Schray A, Bartolovic M, Roesch-Ely D, Aschenbrenner S, Weisbrod M (2017). Relationship between serum calcium and neuropsychological performance might indicate etiological heterogeneity underlying cognitive deficits in schizophrenia and depression. Psychiatry Res, 252:80-86.
[36] Ahn C, Kang J-H, Jeung E-B (2017). Calcium homeostasis in diabetes mellitus. J Vet Sci, 18:261-266.
[37] Arruda AP, S.Hotamisligil G (2015). Calcium Homeostasis and Organelle Function in the Pathogenesis of Obesity and Diabetes. Cell Metab, 22:381-397.
[38] Ouyang L, Zhang W, Du G, Liu H, Xie J, Gu J, et al. (2019). Lead Exposure-Induced Cognitive Impairment through RyR-Modulating Intracellular Calcium Signaling in Aged Rats. Toxicology, 419:55-64.
[39] Underwood M, Sivesind P, Gabourie T (2011). Effect of apoaequorin on cognitive function. Alzheimer's & Dementia, 7:e65.
[40] Milgram NW, Landsberg G, Merrick D, Underwood MY (2015). A novel mechanism for cognitive enhancement in aged dogs with the use of a calcium-buffering protein. J Vet Behav, 10:217-222.
[41] Nicholls DG (2017). Brain mitochondrial calcium transport: Origins of the set-point concept and its application to physiology and pathology. Neurochem Int, 109:5-12.
[42] Workgroup AsACH (2017). Calcium Hypothesis of Alzheimer’s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimer’s & Dementia, 13:178-182.
[43] Rossi A, Pizzo P, Filadi R (2019). Calcium, mitochondria and cell metabolism: A functional triangle in bioenergetics. BBA-Mol Cell Res, 1866:1068-1078.
[44] Guerrero-Hernandez A, Verkhratsky A (2014). Calcium signalling in diabetes. Cell Calcium, 56:297-301.
[45] Jaworska A, Dzbek J, Styczynska M, Kuznicki J (2013). Analysis of calcium homeostasis in fresh lymphocytes from patients with sporadic Alzheimer's disease or mild cognitive impairment. BBA-Mol Cell Res, 1833:1692-1699.
[46] M.Gray S, J.Barrett E (2018). Chapter 11 - The Blood-Brain Barrier in Diabetes Mellitus. Type 2 Diabetes and Dementia:211-229.
[47] Jiang X, Andjelkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, et al. (2018). Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol, 163-164:144-171.
[48] Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A (2018). Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun, 91:34-44.
[49] Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. (2018). Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer's & Dementia, 14:1640-1650.
[50] Duarte-Delgado NP, Vásquez G, Ortiz-Reyes BL (2019). Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Autoimmun Rev, 18:426-432.
[51] Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, et al. (2019). Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacol Res, 141:291-297.
[52] Xu Z, WenZeng, Sun J, Chen W, Zhang R, Yang Z, et al. (2017). The quantification of blood-brain barrier disruption using dynamic contrast-enhanced magnetic resonance imaging in aging rhesus monkeys with spontaneous type 2 diabetes mellitus. NeuroImage, 158:480-487.
[53] Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C, Group tSBS, et al. (2017). Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging, 51:104-112.
[54] C.Lim D, I.Packa A (2014). Obstructive sleep apnea and cognitive impairment: Addressing the blood-brain barrier. Sleep Med Rev, 18:35-48.
[55] Mohamed NA, Gawad HSA (2017). Taurine dietary supplementation attenuates brain, thyroid, testicular disturbances and oxidative stress in streptozotocin-induced diabetes mellitus in male rats. Beni-Suef University Journal of Basic and Applied Sciences, 6:247-252.
[56] Kunze R, H.Marti H (2019). Angioneurins - Key regulators of blood-brain barrier integrity during hypoxic and ischemic brain injury. Prog Neurobiol, 178:1-29.
[57] Zhang S, Dong H, Zhang X, Li N, Sun J, Qian Y (2016). Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption. Behav Brain Res, 298:158-166.
[58] Patell R, Nigmatoulline D, Bena J, Kim DG, Messinger-Rapport B, Lansang MC (2017). Hyperglycemia and Hypoglycemia in Patients with Diabetes in Skilled Nursing Facilities. Endocr Pr, 23:458-465.
[59] Tourkmani AM, Alharbi TJ, Rsheed AMB, AlRasheed AN, AlBattal SM, Abdelhay O, et al. (2018). Hypoglycemia in Type 2 Diabetes Mellitus patients: A review article. Diabetes & Metabolic Syndrome: Clin Res Rev, 12:791-794.
[60] Wiegers EC, Becker KM, Rooijackers HM, Samson-Himmelstjerna FCv, Tack CJ, Heerschap A, et al. (2016). Cerebral blood flow response to hypoglycemia is altered in patients with type 1 diabetes and impaired awareness of hypoglycemia. J Cereb Blood Flow Metab, 37:1994-2001.
[61] Sheen Y-J, Sheu WHH (2016). Association between hypoglycemia and dementia in patients with type 2 dia- betes. Diabetes Res Clin Pr, 116:279-287.
[62] Yuan L, Lingling Z, Ling C, Liting C, Hao L, Huiping L, et al. (2017). Correlation between blood glucose fluctuation and brain damage in neonates with hypoglycemia. J Clin Pediatr, 35:652-654.
[63] Shukla V, Shakya AK, Perez-Pinzon MA, Dave KR (2017). Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation, 14:1-22.
[64] Rehni AK, Dave KR (2018). Impact of Hypoglycemia on Brain Metabolism During Diabetes. Mol Neurobiol, 55:9075-9088.
[65] Xi C, Pan C, Li T (2018). Abnormally low Bispectral index and severe hypoglycemia during maintenance of and recovery from general anesthesia in diabetic retinopathy surgery: two case reports. BMC Anesthesiology, 18:1-4.
[66] Hwang JJ, Parikh L, Lacadie C, Seo D, Lam W, Hamza M, et al. (2018). Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest, 128:1485-1495.
[67] Jackson DA, Michael T, Abreu AVd, Agrawal R, Bortolato M, Fisher SJ (2018). Prevention of Severe Hypoglycemia-Induced Brain Damage and Cognitive Impairment with Verapamil. Diabetes, 67:2107-2112.
[68] Rehni AK, Shukla V, Perez-Pinzon MA, Dave KR (2018). Acidosis mediates recurrent hypoglycemia-induced increase in ischemic brain injury in treated diabetic rats. Neuropharmacology, 135:192-201.
[69] Faiq MA, Dada R, Saluja D, Dada T (2014). Glaucoma-Diabetes of the brain: A radical hypothesis about its nature and pathogenesis. Med Hypotheses, 82:535-546.
[70] Kandimalla R, Thirumala V, Reddy PH (2017). Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta, 1863:1078-1089.
[71] Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, et al. (2017). Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimer’s & Dementia, 13:1327-1336.
[72] Domínguez RO, Pagano MA, Marschoff ER, González SE, Repetto MG, Serra JA (2014). Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. Neurología, 29:567-572.
[73] Pardeshi R, Bolshette N, Gadhave K, Ahire A, Ahmed S, Cassano T, et al. (2017). Insulin signaling: An opportunistic target to minify the risk of Alzheimer’s disease. Psychoneuroendocrinology, 83:159-171.
[74] Beheshti I, Mishra S, Sone D, Khanna P, Matsuda H (2020). T1-weighted MRI-driven Brain Age Estimation in Alzheimer’s Disease and Parkinson’s Disease. Aging Dis, 11:1-11.
[75] Zhang S, Zhi Y, Li F, Huang S, Gao H, Han Z, et al. (2018). Transplantation of in vitro cultured endothelial progenitor cells repairs the blood-brain barrier and improves cognitive function of APP/PS1 transgenic AD mice. J Neurol Sci, 387:6-15.
[76] Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016). Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev, 64:272-287.
[77] Santos CaY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J (2017). Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 7:69-87.
[78] Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, et al. (2017). An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pr, 124:41-47.
[79] Degen C, Toro P, Schönknecht P, Sattler C, Schröder J (2016). Diabetes mellitus Type II and cognitive capacity in healthy aging, mild cognitive impairment and Alzheimer's disease. Psychiatry Res:42-46.
[80] Vieira MNN, Lima-Filho RAS, Felice FGD (2018). Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology, 136:160-171.
[81] Saraswati AP, Hussaini SMA, Krishna NH, Babu BN, Kamal A (2018). Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Eur J Med Chem, 144:843-858.
[82] Zhang Y, Huang N-q, Yan F, Jin H, Zhou S-y, Shi J-s, et al. (2018). Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res, 339:57-65.
[83] Kubis-Kubiak A, Rorbach-Dolata A, Piwowar A (2019). Crucial players in Alzheimer’s disease and diabetes mellitus: Friends or foes? Mechanisms of Ageing and Dev, 181:7-21.
[84] Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018). Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Res Clin Interventions, 4:575-590.
[85] Felice FGD, Lourenco MV, Ferreira ST (2014). How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s & Dementia, 10:S26-S32.
[86] Mushtaq G, Khan JA, Kumosani TA, Kamal MA (2015). Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci, 22:4-13.
[87] C.Bir S, Y.Chernyshev O, Minagar A (2018). Chapter 27-Roles of Toll-Like Receptors in Pathophysiology of Alzheimer’s Disease and Multiple Sclerosis. Neuroinflammation(Second Edition):541-562.
[88] Huang N-Q, Jin H, Zhou S-y, Shi J-s, Jin F (2017). TLR4 is a link between diabetes and Alzheimer’s disease. Behav Brain Res, 316:234-244.
[89] Velazquez R, Tran A, Ishimwe E, Denner L, Dave N, Oddo S, et al. (2017). Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer’s disease. Neurobiol Aging, 58:1-13.
[90] Shinohara M, Sato N (2017). Bidirectional interactions between diabetes and Alzheimer's disease. Neurochem Int, 108:296-302.
[91] Han C, Rice MW, Cai D (2016). Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am J Physiol Endocrinol Metab, 311:E32-E41.
[92] Muriach Ma, Flores-Bellver M, Romero FJ, Barcia JM (2014). Diabetes and the Brain: Oxidative Stress, Inflammation, and Autophagy. Oxid Med Cell Longev, 2014:1-9.
[93] Chen Y-L, Weng S-F, Yang C-Y, Wang J-J, Tien K-J (2019). Diabetic ketoacidosis further increases risk of Alzheimer’s disease in patients with type 2 diabetes. Diabetes Res Clin Pr, 147:55-61.
[94] Tang Y, Li Y-M, Zhang M, Chen Y-Q, Sun Q (2019). ε3/4 genotype of the apolipoprotein E is associated with higher risk of T Alzheimer's disease in patients with type 2 diabetes mellitus. Gene, 703:65-70.
[95] Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N (2010). Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis, 37:67-76.
[96] Mittal K, Katare DP (2016). Shared links between type 2 diabetes mellitus and Alzheimer’s disease: A review. Diabetes & Metabolic Syndrome: Clin Res Rev, 10S:S144-S149.
[97] Li J, Cesari M, Liu F, Dong B, Vellas B (2017). Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review. Can J Diabetes, 41:114-119.
[98] Clark LR, Berman SE, Rivera-Rivera LA, Hoscheidt SM, Darst BF, Engelman CD, et al. (2017). Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer’s disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 7:48-55.
[99] Gejl M, Gjedde A, Brock B, Møller A, Duinkerken Ev, Haahr HL, et al. (2018). Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial. Diabetologia, 61:551-561.
[100] Steculorum SM, Solas M, Brüning JC (2014). The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimer's & Dementia, 10:S3-S11.
[101] Assy MH, Awd M, Elshabrawy AM, Gharieb M (2019). Effect of Ramadan fasting on incidence of cerebrovascular stroke in Egyptian patients with Type 2 Diabetes Mellitus. Res Clin Pr, 151:299-304.
[102] Luitse MJA, Biessels GJ, Rutten GEHM, Kappelle LJ (2012). Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol, 11:261-271.
[103] Mangin G, Poittevin M, Charriaut-Marlangue C, Giannesini C, Merkoulova-Rainon T, Kubis N (2019). Glatiramer acetate reduces infarct volume in diabetic mice with cerebral ischemia and prevents long-term memory loss. Brain Behav Immun, 80:315-327.
[104] Filipov A, Ebert AD, Neumaier-Probst E, Alonso A (2018). The Burden of Diabetes and the Chance of a Previous Stroke: Thrombolysis for Recurrent Stroke in Diabetics. J Stroke Cerebrovascular Dis, 27:1343-1349.
[105] Chen R, Ovbiagele B, Feng W (2016). Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci, 351:380-386.
[106] Shimizu Y, Harashima A, Munesue S, Oishi M, Hattori T, Hori O, et al. (2020). Neuroprotective Effects of Endogenous Secretory Receptor for Advanced Glycation End-products in Brain Ischemia. Aging Dis, 11:1-12.
[107] Braun KF, Otter W, Sandor SM, Standl E, Schnell O (2012). All-cause in-hospital mortality and comorbidity in diabetic and non-diabetic patients with stroke. Diabetes Res Clinical Pr, 98:164-168.
[108] Alloubania A, Saleh A, Abdelhafiz I (2018). Hypertension and diabetes mellitus as a predictive risk factors for stroke. Diabetes & Metabolic Syndrome: Clin Res Rev, 12:577-584.
[109] Chen G, Wang X, Robinson TG, Pikkemaat M, Lindley RI, Zhou S, et al. (2018). Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial. J Neurol Sci, 387:1-5.
[110] Akhtar N, Kamran S, Singh R, Malik RA, Deleu D, Bourke PJ, et al. (2019). The Impact of Diabetes on Outcomes After Acute Ischemic Stroke: A Prospective Observational Study. J Stroke Cerebrovascular Dis, 28:619-626.
[111] Pan Y, Chen W, Wang Y (2019). Prediabetes and Outcome of Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis. J Stroke Cerebrovascular Dis, 28:683-692.
[112] Sun Y, Toh MPHS (2009). Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore. Value Health, 12:S101-S105.
[113] Elgebaly MM, Arreguin J, Storke N (2019). Targets, Treatments, and Outcomes Updates in Diabetic Stroke. J Stroke Cerebrovascular Dis, 28:1413-1420.
[114] Jun-Min C, Xiang-Jian Z, Xiao-Xia L, De-Gang S, Xiao-Yun C, Qian S (2018). Pericytes and Central Nervous System Diseases. Chin J Stroke, 13:90-95.
[115] Zhong W, Yuan Y, Gu X, Kim SI-y, Chin R, Loye M, et al. (2020). Neuropsychological Deficits Chronically Developed after Focal Ischemic Stroke and Beneficial Effects of Pharmacological Hypothermia in the Mouse. Aging Dis, 11:1-16.
[116] Yan W, Zhao X, Chen H, Zhong D, Jin J, Qin Q, et al. (2016). β-Dystroglycan cleavage by matrix metalloproteinase-2/-9 disturbs aquaporin-4 polarization and influences brain edema in acute cerebral ischemia. Neuroscience, 326:141-157.
[117] Villalba H, Shah K, Albekairi TH, Sifat AE, Vaidya B, Abbruscato TJ (2018). Potential role of myo-inositol to improve ischemic stroke outcome in diabetic mouse. Brain Res, 1699:166-176.
[118] Fuentes B (2018). Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist’s point of view. Medicina Clinica, 150:275-281.
[119] Rehni AK, Liu A, Perez-Pinzon MA, Dave KR (2017). Diabetic aggravation of stroke and animal models. Exp Neurol, 292:63-79.
[120] Boyko M, Zvenigorodsky V, Grinshpun J, Shiyntum HN, Melamed I, Kutz R, et al. (2019). Establishment of novel technical methods for evaluating brain edema and lesion volume in stroked rats: A standardization of measurement procedures. Brain Res, 1718:12-21.
[1] Peng Yu, Poornima Venkat, Michael Chopp, Alex Zacharek, Yi Shen, Linlin Liang, Julie Landschoot-Ward, Zhongwu Liu, Rongcai Jiang, Jieli Chen. Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice[J]. Aging and disease, 2019, 10(4): 770-783.
[2] Xu-Xu Deng, Shan-Shan Li, Feng-Yan Sun. Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling[J]. Aging and disease, 2019, 10(4): 807-817.
[3] Zhi-Ying Tian, Chun-Yan Wang, Tao Wang, Yan-Chun Li, Zhan-You Wang. Glial S100A6 Degrades β-amyloid Aggregation through Targeting Competition with Zinc Ions[J]. Aging and disease, 2019, 10(4): 756-769.
[4] Takehiko Yamanaka, Yuto Uchida, Keita Sakurai, Daisuke Kato, Masayuki Mizuno, Toyohiro Sato, Yuta Madokoro, Yuko Kondo, Ayuko Suzuki, Yoshino Ueki, Fumiyasu Ishii, Cesar V Borlongan, Noriyuki Matsukawa. Anatomical Links between White Matter Hyperintensity and Medial Temporal Atrophy Reveal Impairment of Executive Functions[J]. Aging and disease, 2019, 10(4): 711-718.
[5] Yu-Sheng Li, Zhi-Hua Yang, Yao Zhang, Jing Yang, Dan-Dan Shang, Shu-Yu Zhang, Jun Wu, Yan Ji, Lu Zhao, Chang-He Shi, Yu-Ming Xu. Two Novel Mutations and a de novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease[J]. Aging and disease, 2019, 10(4): 908-914.
[6] Qing-Qing Tao, Yu-Chao Chen, Zhi-Ying Wu. The role of CD2AP in the Pathogenesis of Alzheimer's Disease[J]. Aging and disease, 2019, 10(4): 901-907.
[7] Fei Han, Xiaochen Li, Juhong Yang, Haiyi Liu, Yi Zhang, Xiaoyun Yang, Shaohua Yang, Bai Chang, Liming Chen, Baocheng Chang. Salsalate Prevents β-Cell Dedifferentiation in OLETF Rats with Type 2 Diabetes through Notch1 Pathway[J]. Aging and disease, 2019, 10(4): 719-730.
[8] Navneet Kumar Dubey, Hong-Jian Wei, Sung-Hsun Yu, David F. Williams, Joseph R. Wang, Yue-Hua Deng, Feng-Chou Tsai, Peter D. Wang, Win-Ping Deng. Adipose-derived Stem Cells Attenuates Diabetic Osteoarthritis via Inhibition of Glycation-mediated Inflammatory Cascade[J]. Aging and disease, 2019, 10(3): 483-496.
[9] Rongrong Han, Zeyue Liu, Nannan Sun, Shu Liu, Lanlan Li, Yan Shen, Jianbo Xiu, Qi Xu. BDNF Alleviates Neuroinflammation in the Hippocampus of Type 1 Diabetic Mice via Blocking the Aberrant HMGB1/RAGE/NF-κB Pathway[J]. Aging and disease, 2019, 10(3): 611-625.
[10] Xianmei Li, Siyang Lin, Xiaoli Chen, Wensi Huang, Qian Li, Hongxia Zhang, Xudong Chen, Shaohua Yang, Kunlin Jin, Bei Shao. The Prognostic Value of Serum Cytokines in Patients with Acute Ischemic Stroke[J]. Aging and disease, 2019, 10(3): 544-556.
[11] Huachen Huang, Shanshan Song, Suneel Banerjee, Tong Jiang, Jinwei Zhang, Kristopher T. Kahle, Dandan Sun, Zhongling Zhang. The WNK-SPAK/OSR1 Kinases and the Cation-Chloride Cotransporters as Therapeutic Targets for Neurological Diseases[J]. Aging and disease, 2019, 10(3): 626-636.
[12] Saumyendra N. Sarkar, Ashley E. Russell, Elizabeth B. Engler-Chiurazzi, Keyana N. Porter, James W. Simpkins. MicroRNAs and the Genetic Nexus of Brain Aging, Neuroinflammation, Neurodegeneration, and Brain Trauma[J]. Aging and disease, 2019, 10(2): 329-352.
[13] Christopher Bi, Stephanie Bi, Bin Li. Processing of Mutant β-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer’s Disease[J]. Aging and disease, 2019, 10(2): 383-403.
[14] Seong Gak Jeon, Eun Ji Song, Dongje Lee, Junyong Park, Yunkwon Nam, Jin-il Kim, Minho Moon. Traditional Oriental Medicines and Alzheimer’s Disease[J]. Aging and disease, 2019, 10(2): 307-328.
[15] Yuanyuan Ma, Yanqun Liu, Zhijun Zhang, Guo-Yuan Yang. Significance of Complement System in Ischemic Stroke: A Comprehensive Review[J]. Aging and disease, 2019, 10(2): 429-462.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd